PRM66 The world health organization and universal diagnostic testing for suspected malaria in children: is the new policy cost-effective and affordable for sub-saharan africa?  by Phillips, V.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  A21
ondary aim of this analysis is to promote an approach to develop more reliable disease 
simulation models in cardiovascular disease. Methods: Data describing LDL-C and 
nfMI+CV Death outcomes were abstracted from several landmark secondary preven-
tion statin trials in clinically stable patient populations (4S, CARE, LIPID, HPS, TNT, 
IDEAL, GREACE, AVERT, and LIPS). Linear (L), quadratic (Q), one-knot linear spline 
(S1L) and two-knot quadratic spline (S2Q) models were fit. RMSE, leave-one-out cross 
validated (LOOCV) and Monte Carlo cross validated (MCCV) RMSE (90% training, 1,000 
replicates) were used to evaluate predictive performance. Predicted event rates based 
on LDL-C = 50mg/dL were estimated to illustrate the clinical implications of each 
model. To encourage full reproducibility and transparency, all raw data and code (R) 
will be made freely available for download online via authors Git repository. Results: 
A total of eight models were fit and evaluated, including four distinct functional 
forms (L, Q, S1L, and S2Q) across two sets of data (all data (A) and data censured for 
high leverage studies(C)). Of all the models evaluated, S2Q-C exhibited the lowest 
RMSE (0.317) while L-C produced both the lowest LOOCVRMSE (0.463) and MCCVRMSE 
(0.389). Model selection had an impact on predicted percentage of events/yr at 50mg/
dL (range= 0.769 to 2.09). ConClusions: This analysis suggests that a linear model 
may be among the most appropriate when describing the relationship between LDL 
and nfMI+CV Death in secondary prevention; however, other models (linear spline 
and quadratic) warrant further investigation. These findings along with additional 
research will help inform more reliable and accurate models of long-term outcomes 
and economic benefit of LDL-C lowering treatment modalities.
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objeCtives: Malaria imposes a substantial global disease burden with 198 million 
cases reported worldwide in 2013. It disproportionately affects sub-Saharan Africa, 
particularly young children and accounts for 14% of the region’s childhood deaths. 
In an effort to improve disease management, the World Health Organization (WHO) 
in 2010 recommended countries test children (age < 5) who present with suspected 
malaria fever and confirm diagnosis rather than treat them presumptively with 
antimalarial drugs, the standard of care to date. While all 47 African countries 
designated as malaria-endemic, have adopted the policy, significant barriers to 
implementation exist. These include costs, uncertainty about the overall health 
benefits, shortfalls in testing supplies and physician practice patterns. Methods: 
We use a decision-analytic approach to assess the policy’s cost effectiveness in three 
countries in sub-Saharan Africa: Angola, Tanzania and Uganda, each representing 
different prevalence/income combinations. Our model includes country-specific 
epidemiologic, cost and behavioral data, including that of physician and caregiver. 
Our primary data sources are national Malaria Indicator Surveys and information 
from each country’s National Malaria Control Program. We use a Markov specifi-
cation to account for multiple fever episodes and estimate the incremental cost-
effectiveness of the testing policy through two-stage micro-simulation models. 
These models capture key dimensions of uncertainty associated with our projec-
tions. Results: We find that diagnostic testing for malaria is cost-saving in Angola. 
In Tanzania the cost per life-year gained is $5.54 and $94.58 in Uganda. Both are cost-
effective compared to the WHO standard of $150 per life-year gained. Our results 
are robust under varying cost, prevalence and behavioral assumptions. Probabilistic 
sensitivity analyses indicate that testing is cost-saving or cost-effective: 80% of the 
time in Angola, 89% in Tanzania, and 69% in Uganda. ConClusions: Our findings 
strongly suggest pursuit of policies that facilitate full implementation of testing, 
including promoting clinician adherence to test results.
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objeCtives: The concept of whole-disease model has rarely been applied in prac-
tice or considered in the published literature. No studies to date have addressed the 
applicability of this approach in rare diseases. This research aims to demonstrate 
the applicability, technique, and framework of the model designed to educate US 
Payers of the estimated patient-level costs and resource utilization, using a rare 
disease as a case study. Methods: The lack of specific ICD-9-CM code, prevalence 
overestimation, poorly documented US epidemiology data, complex diagnostics, 
and off-label pharmacotherapy were evident in rare diseases. In order to estimate 
patient-level resource utilization, diagnosis costs, and 12-month treatment cost 
from the US Payer’s perspective, a clinical guideline-based approach was developed. 
We reviewed diagnosis and treatment guideline recommendations to develop a 
resource utilization algorithm which was subsequently validated by clinicians to 
reflect the real-world clinical practice. Model cost inputs were derived from pub-
lished resources including the most recent year Medicare Fee Schedules and H-CUP 
National Inpatient Sample database. Adverse event costs associated with the treat-
ments were not accounted for in the model. Results: An interactive, MS-Excel 
based economic model was constructed based on guideline recommendations. The 
model inputs were customizable, allowing flexibility in plan/Payer specific disease 
burden estimation. Cost of diagnosis, pharmacotherapy, and surgical therapies were 
calculated for a single patient over a 12-month period. ConClusions: The study 
demonstrates that the whole-disease model approach can be applied to rare dis-
eases to provide the disease burden estimation, serving as an information tool for 
Payers, for diseases with small patient volume and unknown cost burden. The model 
also provides a platform for manufacturers to: 1) incorporate real-world data as they 
become available; 2) add/remove interventions as the market evolves and; 3) add 
various economic elements to further calculate budget impact or cost-effectiveness 
of an intervention over a product life-cycle.
unvaccinated with the seasonal influenza vaccine and persons vaccinated during 
seasons where vaccine was considered (by the CDC-reported vaccine effective-
ness percentage (VE%= (1-relative risk)*100%)) a suboptimal match for seasonal 
flu strain. Results: Published vaccine effectiveness for a suboptimal seasonal 
influenza vaccination ranged from 39%-63% from flu seasons 2006-2007 through 
2013-2014. This was approximately the same protection observed in the large claims 
database for the same year ranges. When modeled together with cost it was shown 
that this mismatch of vaccination to circulating virus still equated to a substantial 
reduction in burden of disease when vaccinated. Validation of results still ongo-
ing. ConClusions: The burden of disease of influenza significantly decreases 
even when the seasonal influenza vaccine is a suboptimal match to the prevalent 
circulating strain. It is recommended that all persons able to receive the influenza 
vaccination do so, whether or not the match is optimal. It has been demonstrated 
that a suboptimal match effectively decreases the burden of the disease.
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objeCtives: Value of Information (VOI) analyses can help align research investments 
with areas that could have the greatest impact on patient outcomes, but many ques-
tions remain concerning its feasibility and acceptability to inform real-world prior-
itization decisions. Our objective was to develop a process for calculating VOI in “real 
time” to inform trial funding decisions within SWOG, a large cancer clinical trials 
group. Methods: We adapted a novel and efficient modeling approach - minimal 
modeling VOI - using a sample of nine phase II/III trial proposals from the Breast, 
Gastrointestinal, and Genitourinary committees reviewed by SWOG’s leadership 
between 2008-2013. We created decision models for each trial proposal and devised 
an efficient process to characterize prior uncertainty in treatment effect by linking 
evidence-based assumptions in a trial’s sample size calculations with the historical 
success rates of SWOG trials. Expected clinical and economic VOI was calculated using 
Bayesian updating methods. We customized the process using iterative stakeholder 
input. Results: The VOI modeling process was feasible and sufficiently captured key 
expected differences in comprehensive outcomes and attendant uncertainty for 8 of 9 
trial proposals. Model construction and calculations took one researcher < 1 week per 
proposal. We accommodated stakeholder input by: a) deconstructing VOI metrics into 
expected health benefits and incremental healthcare costs, b) assuming treatment 
decisions were based on health benefits alone, and c) providing both individual and 
population level results. Following this customization, SWOG generally accepted the 
VOI framework and results for the retrospective analyses and felt that VOI analyses 
would likely be useful in informing future trial proposal evaluations. ConClusions: 
We developed an efficient and customized process for calculating the expected VOI 
of cancer clinical trials that is feasible for use in real-time decision-making and is 
acceptable to stakeholders. Prospective use and assessment of this approach is cur-
rently underway within SWOG.
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objeCtives: Generating multivariate random variables is essential in disease 
simulation applications. In this study we examine the implications of alternative 
approaches to generate marginal distributions and correlation matrix on simula-
tion outcomes. Methods: We adopt three alternative methods including Cholesky 
Decomposition (CD), CD with conditional matching, and the NORmal-To-Anything 
(NORTA) method to generate a hypothetical simulation sample with arbitrary mar-
ginal distributions and correlation matrix. As the comparator, we also create an 
independent and identically distributed (iid) simulation sample. The samples are 
individually populated in a previously developed type 2 diabetes microsimulation 
model to predict the major clinical endpoints over 15 years. The endpoints include 
all-cause mortality, diabetes-related mortality, and major cardiovascular events. We 
examine the goodness of fit by total deviance, i.e., the aggregated values of the rela-
tive difference between the individual predictions with the endpoints observed in the 
actual data, in the overall and stratified samples. Results: The results show that, 
the model predications deviate from the observed data with an iid sample. Over 15 
years, the model over-predicts all the numbers of endpoint events by 20%, with the 
total deviance of 0.73, and the over-prediction is particularly more pronounced in the 
younger patients. With a sample of a constructed multivariate normal distribution 
using the CD and CD plus conditional matching approach, the deviance is reduced 
to 0.41 and 0.58 respectively. A further improvement is observed when using the 
NORTA method, with the deviance of the endpoints between model prediction and 
actual data further reduced to 0.11. The reduction was mainly contributed by better 
approximations in the dispersion of the risk factors among patients. ConClusions: 
Random sequences generation has important ramification for simulation outcomes. 
Poorly-defined multivariate distributions may significantly distort the simulation 
performance. Given its flexibility for both continuous and discrete variables, NORTA 
method appears to be a preferable approach.
PRM65
an evaluaTion of coMPeTing Models foR PRedicTing cv evenT RaTes 
fRoM ldl-c levels in secondaRy PRevenTion
Conner C.
Health Strategy, LLC, Remdond, WA, USA
objeCtives: This study aims to evaluate four alternative models that each describe 
the relationship between LDL-C and CV event rates in secondary prevention. A sec-
